NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading IVVD? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making and has mixed management execution, but it operates in a sector with favorable tailwinds that could support its recovery.
The market appears to have priced in a low level of fragility, suggesting that it does not expect significant negative changes in the near term. However, IVVD is seen as cheap compared to its peers, indicating that expectations for future performance are low.
Fundamentals may struggle in the near term due to weak recent financial performance and a high probability of missing earnings expectations. Management is focused on increasing revenue from PEMGARDA and advancing clinical programs, but results have been mixed.
The long-term thesis hinges on whether sector leaders like VRTX, REGN, and ARGX continue to perform well and guide higher. Additionally, any negative guidance from IVVD could significantly impact sentiment and performance.
Over the next 1 to 3 years, IVVD's prospects will depend on its ability to navigate sector dynamics and improve its financial performance. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Another earnings miss could signal deeper issues in the business. It may affect investor trust and stock performance.
Confirms:The company reports another earnings miss in the next quarter.
Disproves:Earnings meet or exceed expectations in the next quarter.
Why it matters: Top-line results will indicate VYD2311's effectiveness against COVID-19. This could shape future sales and strategy.
Confirms one read:VYD2311 works over 70% of the time to prevent COVID-19 symptoms.
Confirms the other:VYD2311 works less than 50% of the time. This raises worries about its market success.
Why it matters: If revenue growth speeds up, it may show a good change for Invivyd.
Confirms:Health Care sector revenue growth speeds up to 10% or more.
Disproves:Revenue growth keeps slowing down below current levels.
Why it matters: If sector revenue growth drops, it could impact Invivyd's performance. The health care sector is currently in a growth phase.
Confirms:Sector revenue growth falls below its median for the first time in two years.
Disproves:Sector revenue growth remains above its median.
Why it matters: Earnings results will show how well the company is managing its growth and costs after the recent earnings miss.
Confirms one read:Earnings per share (EPS) beats analyst expectations.
Confirms the other:Earnings per share (EPS) did not meet what analysts expected again.
Why it matters: Earnings results will provide insight into the company's financial health and growth trajectory. A miss could signal deeper issues.
Confirms:The earnings report shows a profit. It meets what analysts expected.
Disproves:The earnings report shows a loss. It misses analyst expectations by a lot.
Why it matters: PEMGARDA is growing. This shows strong market demand, even as vaccine use drops.
Confirms:In Q2 2026, PEMGARDA made over $15 million. This shows it is still growing.
Disproves:In Q2 2026, PEMGARDA made less than $13 million. This suggests demand is falling.
Why it matters: VMS063 could help Invivyd offer more options and meet needs in measles care.
Confirms:VMS063 reaches IND readiness by late 2026 as planned.
Disproves:VMS063 development is delayed. It will not be ready for IND until after late 2026.
